Nurse Practitioner, Family · Philadelphia, PA
NPI
1528387255
Since 2010
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
809 Locust St
Philadelphia, PA, 19107
Phone (215) 563-0658
Groups this clinician bills Medicare through
Medicare paid, 2024
$3,790
91 services
Medicare patients, 2024
32
Average age 59
Drug cost, 2024
$2.5M
1,259 prescriptions
Company payments, 2023
$211
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maxwell A Parrish was code 99214 (office e&m - established), 41 times for 25 patients. In total Maxwell A Parrish billed 91 services in 6 codes, and Medicare paid $3,790.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 41 | 25 | $58.00 | $2,378 |
| 99213 Office E&M - Established | Facility | 18 | 11 | $30.26 | $545 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 17 | 15 | $7.96 | $135 |
By year: 2022 $4,123 for 79 services; 2023 $3,387 for 75 services; 2024 $3,790 for 91 services.
Medicare prescription drug claims, 2024
In 2024, the drug Maxwell A Parrish prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 172 prescriptions and refills. In total Maxwell A Parrish wrote 1,259 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 172 | 172 | 19 | $668K |
| Tivicay Dolutegravir Sodium | 98 | 116 | 14 | $263K |
| Descovy Emtricitabine/Tenofov Alafenam | 63 | 79 | Under 11 | $169K |
| Dovato Dolutegravir Sodium/Lamivudine | 58 | 78 | Under 11 | $223K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 54 | 62 | Under 11 | $689 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 46 | 46 | Under 11 | $1,516 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 46 | 46 | Under 11 | $182K |
| Darunavir Generic | 42 | 42 | Under 11 | $50K |
| Prezcobix Darunavir/Cobicistat | 39 | 41 | Under 11 | $94K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 35 | 35 | Under 11 | $129K |
| Atorvastatin Calcium Generic | 35 | 71 | Under 11 | $289 |
| Cabenuva Cabotegravir/Rilpivirine | 29 | 41 | Under 11 | $160K |
| Fluoxetine Hcl Generic | 23 | 23 | Under 11 | $1,702 |
| Stribild Elviteg/Cob/Emtri/Tenofo Disop | 23 | 23 | Under 11 | $98K |
| Juluca Dolutegravir/Rilpivirine | 23 | 29 | Under 11 | $89K |
Brand drugs: 749 claims; generic drugs: 510 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Maxwell A Parrish $211 ($211 in general payments such as food, travel and fees) from 2 companies. The largest payer was Merck Sharp & Dohme LLC with $109.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.